These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 9235795)

  • 1. [Pathophysiological mechanisms of the renin-angiotensin system and its pharmacologic modification by ACE inhibitors or angiotensin II (type 1) receptor blockers in cardiovascular diseases].
    Huber K; Pachinger O; Pichler M; Klein W
    Z Kardiol; 1997 Apr; 86(4):239-50. PubMed ID: 9235795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
    Haddad G; Amiri F; Garcia R
    Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
    Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
    Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II type 1 receptor blockade: a novel therapeutic concept.
    Johnston CI
    Blood Press Suppl; 2000; 1():9-13. PubMed ID: 11059629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Spinale FG; de Gasparo M; Whitebread S; Hebbar L; Clair MJ; Melton DM; Krombach RS; Mukherjee R; Iannini JP; O SJ
    Circulation; 1997 Oct; 96(7):2385-96. PubMed ID: 9337215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of the selective blocking of angiotensin II receptors in the treatment of cardiovascular diseases].
    Carnovali M
    Clin Ter; 2001; 152(2):103-6. PubMed ID: 11441521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M
    Rev Prat; 2004 Jun; 54(11):1167-74. PubMed ID: 15496022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A; Divchev D; Luchtefeld M; Schieffer B
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theoretical basis and clinical evidence for differential effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor subtype 1 blockers.
    Weir MR; Henrich WL
    Curr Opin Nephrol Hypertens; 2000 Jul; 9(4):403-11. PubMed ID: 10926177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.
    Stergiou GS; Skeva II
    Curr Top Med Chem; 2004; 4(4):473-81. PubMed ID: 14965313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice.
    Xu J; Carretero OA; Liu YH; Shesely EG; Yang F; Kapke A; Yang XP
    Hypertension; 2002 Sep; 40(3):244-50. PubMed ID: 12215461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of angiotensin receptor antagonists in heart failure: clinical and experimental aspects.
    Regitz-Zagrosek V; Neuss M; Fleck E
    Eur Heart J; 1995 Dec; 16 Suppl N():86-91. PubMed ID: 8682068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin system and experimental heart failure.
    Wollert KC; Drexler H
    Cardiovasc Res; 1999 Sep; 43(4):838-49. PubMed ID: 10615411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor blockers: evidence for preserving target organs.
    Carson P; Giles T; Higginbotham M; Hollenberg N; Kannel W; Siragy HM
    Clin Cardiol; 2001 Mar; 24(3):183-90. PubMed ID: 11288962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism.
    Brunner-La Rocca HP; Vaddadi G; Esler MD
    J Am Coll Cardiol; 1999 Apr; 33(5):1163-73. PubMed ID: 10193712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade.
    Tschöpe C; Schultheiss HP; Walther T
    J Cardiovasc Pharmacol; 2002 Apr; 39(4):478-87. PubMed ID: 11904521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin receptors: physiology and pharmacology.
    Guthrie GP
    Clin Cardiol; 1995 Jun; 18(6 Suppl 3):III 29-34. PubMed ID: 7634561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.